|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q3 FY2022
As of Sep 30, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||
| Investments at fair value | |||||||||||||||
| Non-controlled/Non-affiliated Investments | |||||||||||||||
| Non-controlled/Affiliated Investments | |||||||||||||||
| Controlled Investments | |||||||||||||||
| Total investments at fair value | |||||||||||||||
| Cash and cash equivalents | |||||||||||||||
| Foreign currencies (cost - $108 and $1,286, respectively) | |||||||||||||||
| Receivable for investments sold | |||||||||||||||
| Interest receivable | |||||||||||||||
| Dividends receivable | |||||||||||||||
| Deferred financing costs | |||||||||||||||
| Unrealized appreciation on foreign currency forward contracts | |||||||||||||||
| Prepaid expenses and other assets | |||||||||||||||
| Total Assets | |||||||||||||||
| Liabilities | |||||||||||||||
| Debt (net of deferred financing costs and unamortized original discount of 5,396 and 5,838, respectively) | |||||||||||||||
| Payable for investments purchased | |||||||||||||||
| Management and performance-based incentive fees payable | |||||||||||||||
| Shares Repurchase Payable | |||||||||||||||
| Management fees payable | |||||||||||||||
| Performance-based incentive fees payable | |||||||||||||||
| Interest payable | |||||||||||||||
| Accrued administrative services expense | |||||||||||||||
| Unrealized depreciation on foreign currency forward contracts | |||||||||||||||
| Other liabilities and accrued expenses | |||||||||||||||
| Total Liabilities | |||||||||||||||
| Net Assets | |||||||||||||||
| Net Assets | |||||||||||||||
| Common stock, $0.001 par value (130,000,000 shares authorized; 82,372,628 and 92,211,869 shares issued and outstanding, respectively) | |||||||||||||||
| Capital in excess of par value | |||||||||||||||
| Accumulated under-distributed (over-distributed) earnings | |||||||||||||||
| Net Assets | |||||||||||||||
| Net assets at beginning of period | |||||||||||||||
| Net Asset Value Per Share |
Loading...
